Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7745371 | 0.86 | SMN1; SMN2 (0.45) | PTPN1ALDH1A1POLBSMN1; SMN2CHRM5 | |
| SCHEMBL6658347 | 0.80 | ESR2 (0.43) | PTPN1ALDH1A1SMN1; SMN2CHRM1CHRM2 | |
| SCHEMBL9640940 | 0.73 | LMNA (0.33) | ALDH1A1CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL7740552 | 0.69 | SMN1; SMN2 (0.47) | ALDH1A1POLBSMN1; SMN2KMT2AKDM4E | |
| SCHEMBL27555817 | 0.68 | KMT2A (0.32) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL6952329 | 0.66 | ESR2 (0.39) | SMN1; SMN2 | |
| SCHEMBL17105128 | 0.65 | MEN1 (0.51) | HTTSMN1; SMN2KMT2A | |
| SCHEMBL5405289 | 0.64 | ALDH1A1 (0.46) | ALDH1A1POLBHTTSMN1; SMN2KDM4E | |
| SCHEMBL9177301 | 0.64 | MEN1 (0.53) | ALDH1A1HTTSMN1; SMN2KMT2AGAA | |
| SCHEMBL14855693 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080075-B1 | PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES | AVENTIS PHARMA INC (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040067988-A1 | Piperididinyl and N-amidinopiperidinyl derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2004-04-08 | — | — | US | disclosed |
| US-20020016339-A1 | Piperididinyl and N-amidinopiperidinyl derivatives | KLEIN SCOTT I (US) | 2002-02-07 | — | — | US | disclosed |
| US-6277865-B1 | ANTICOAGULANTS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016339-A1 | Piperididinyl and N-amidinopiperidinyl derivatives | F11, F5, TFPI | PTPN1 3791/4885ALDH1A1 1660/4885POLB 1730/4885 |
| US-20040067988-A1 | Piperididinyl and N-amidinopiperidinyl derivatives | TFPI, F2, SERPINC1 | PTPN1 3727/4885ALDH1A1 1920/4885POLB 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.